Drug repositioning: a brief overview

被引:245
作者
Jourdan, Jean-Pierre [1 ,2 ]
Bureau, Ronan [1 ]
Rochais, Christophe [1 ]
Dallemagne, Patrick [1 ]
机构
[1] Normandie Univ., CERMN, UNICAEN, F-14032 Caen, France
[2] CHRU Caen, Pharm Dept, Caen, France
关键词
drug; generic; indication; repositioning;
D O I
10.1111/jphp.13273
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objectives Drug repositioning, that is, the use of a drug in an indication other than the one for which it was initially marketed, is a growing trend. Its origins lie mainly in the attrition experienced in recent years in the field of new drug discovery. Key findings Despite some regulatory and economic challenges, drug repositioning offers many advantages, and a number of recent successes have confirmed both its public health benefits and its commercial value. The first examples of successful drug repositioning mainly came about through serendipity like acetylsalicylic acid, thalidomide, sildenafil or dimethylfumarate. Conclusion The history of great-repositioned drugs has given some solutions to various pathologies. Serendipity is not yet useful to find repositioning drugs. Drug repositioning is of growing interest. Nowadays, a more rational approach to the identification of drug candidates for repositioning is possible, especially using data mining.
引用
收藏
页码:1145 / 1151
页数:7
相关论文
共 23 条
  • [1] Drug repositioning: Identifying and developing new uses for existing drugs
    Ashburn, TT
    Thor, KB
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (08) : 673 - 683
  • [2] A standard database for drug repositioning
    Brown, Adam S.
    Patel, Chirag J.
    [J]. SCIENTIFIC DATA, 2017, 4
  • [3] Cavalla D, 2017, FRONT NEUROTHER SER, P3
  • [4] Chloroquine and hydroxychloroquine as available weapons to fight COVID-19
    Colson, Philippe
    Rolain, Jean-Marc
    Lagier, Jean-Christophe
    Brouqui, Philippe
    Raoult, Didier
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2020, 55 (04)
  • [5] Cummings Jeffrey, 2017, Alzheimers Dement (N Y), V3, P367, DOI 10.1016/j.trci.2017.05.002
  • [6] Laying in silico pipelines for drug repositioning: a paradigm in ensemble analysis for neurodegenerative diseases
    Dovrolis, Nikolas
    Kolios, George
    Spyrou, George
    Maroulakou, Loanna
    [J]. DRUG DISCOVERY TODAY, 2017, 22 (05) : 805 - 813
  • [7] Systematic Drug Repositioning for a Wide Range of Diseases with Integrative Analyses of Phenotypic and Molecular Data
    Iwata, Hiroaki
    Sawada, Ryusuke
    Mizutani, Sayaka
    Yamanishi, Yoshihiro
    [J]. JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2015, 55 (02) : 446 - 459
  • [8] Drug repositioning and repurposing: terminology and definitions in literature
    Langedijk, Joris
    Mantel-Teeuwisse, Aukje K.
    Slijkerman, Diederick S.
    Schutjens, Marie-Helene D. B.
    [J]. DRUG DISCOVERY TODAY, 2015, 20 (08) : 1027 - 1034
  • [9] On the Integration of In Silico Drug Design Methods for Drug Repurposing
    March-Vila, Eric
    Pinzi, Luca
    Sturm, Noe
    Tinivella, Annachiara
    Engkvist, Ola
    Chen, Hongming
    Rastelli, Giulio
    [J]. FRONTIERS IN PHARMACOLOGY, 2017, 8
  • [10] Monneret C., 2009, Fabuleux hasards: histoire de la dcouverte de mdicaments